Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Financing › Details

CellGenix–Sartorius: investment, 202107 acquisition 51% share for €100m cash by SSB with planned acquisition of remaining shares until 2026

 

Period Period 2021-07-02
Organisations Money taker CellGenix GmbH
  Group Sartorius (Group)
  Money source Sartorius Stedim Biotech S.A. (SSB)
  Group Sartorius (Group)
Product Product cell culture media
Persons Person Fáber, René (Sartorius 202010 Head of Bioprocess Solutions Division)
  Person 2 Rosenthal, Felicia (CellGenix 200501 Managing Director before Metreon Bioproducts 1996– BIO Deutschland 200501)
     

Sartorius AG. (7/2/21). "Press Release: Sartorius Strengthens Product Portfolio for Cell and Gene Therapies by Acquiring a Majority Stake in CellGenix". Göttingen.

> Portfolio expanded by cell culture components, such as growth factors, cytokines, and media

> CellGenix site in Freiburg to be expanded into a center of excellence for the development and production of cell culture components


The life science group Sartorius, through its subgroup Sartorius Stedim Biotech, has acquired a majority stake in the reagent manufacturer CellGenix GmbH. The company based in Freiburg, Germany, and with a sales subsidiary near the biotechnology hub in Boston, Massachusetts USA, produces and markets cell culture components, such as growth factors, cytokines and media in GMP quality for manufacturing cell and gene therapy products.

Sartorius has initially acquired 51 percent of this company, which has been privately owned until now, for around 100 million euros in cash. At the beginning of 2023 and 2026, Sartorius plans to acquire the remaining shares of CellGenix. Founded in 1994 at the University Medical Center of Freiburg, CellGenix currently employs some 70 people and generated sales of more than 20 million euros in 2020, achieving a very significant double-digit EBITDA margin.

“CellGenix has an excellent reputation on the market and brings in high technological expertise and considerable regulatory experience in one of the fastest-growing fields of the biopharma sector. Together, we will support our customers even better in fast-tracking their drug candidates efficiently through the various steps in the development of medicines so that innovative therapies can reach patients faster,” said René Fáber, member of the Executive Board for the Bioprocess Solutions Division of Sartorius.

“For us, Sartorius is an ideal partner with a highly complementary product portfolio that will accelerate our development with its global sales team, enabling us to usher in our next phase of growth,” added Felicia Rosenthal, CEO and co-founder of CellGenix.

Sartorius plans to expand the Freiburg site substantially and to establish it as a center of excellence within the group in the areas of development and manufacture of quality critical raw materials for the cell and gene therapy market.


This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version.


A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.


Contact

Petra Kirchhoff
Corporate Communications & Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
sartorius.com

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.

   
Record changed: 2021-07-02

Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

More documents for Sartorius (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Excelya CRO We Care for Your Clinical Trials 650x80px




» top